摘要
目的：比较氨磺必利与利培酮治疗首发精神分裂症（first-episode schizophrenia，FES）的安全性及有效性。方法连续选择80例 FES 患者，根据随机数字表法将其分为观察组（n ＝40，口服氨磺必利）及对照组（n ＝40，口服利培酮）；比较两组总有效率、阳性及阴性症状量表（positive and negative symptoms scale， PANSS）评分及不良反应发生率。结果治疗1周后，观察组阴性症状评分显著低于对照组[（20．89±3.07）分比（18．15±3.64）分；t ＝3．639，P ＝0．001]。治疗8周后，两组 PANSS 总分及分量表评分差异均无统计学意义（均 P 〉0．05）；观察组、对照组总有效率分别为90．00％、82．50％，观察组、对照组不良反应发生率分别为17.50％、27．50％，差异均无统计学意义（χ^2＝0．949，P ＝0．330；χ^2＝1．147，P ＝0．284）。结论氨磺必利与利培酮对 FES 的疗效及安全性相当，但氨磺必利早期改善患者阴性症状疗效更佳。
Objective To compare and analyze the efficacy and safety of amisulpride and risperidone in the treatment of patients with first -episode schizophrenia（FES）.Methods 80 patients with FES were randomly divided into the observation group （n =40,orally given amisulpride）and the control group （n =40,orally given risperidone） according to random number table.The total effective rate,positive and negative symptoms scale （PANSS）,adverse reaction rate of two groups were compared.Results 1 week after treatment,the negative symptoms score of the observation group was significantly lower than that of the control group [（20.89 ±3.07 ）points vs.（18.15 ± 3.64）points,t =3.639,P =0.001].8 weeks after treatment,the PANSS scores and factor score of the two groups had no significant differences（all P 〉0.05）.The total effective rate and adverse reaction rate of the observation group were 90.00%,17.50% respectively,which of the control group were 82.50%,27.50% respectively,there were no＆amp;nbsp;statistically significant differences （χ^2 =0.949,P =0.330;χ^2 =1.147,P =0.284）.Conclusion Amisulpride and risperidone has similar efficacy and safety in the treatment of patients with FES,but amisulpride has better early effect in improving negative symptoms.
作者
詹同宝
Zhan Tongbao(Department of Psychiatry, the Fourth People＇s Hospital of Huainan, H uainan,Anhui 232052, Chin)
出处
《中国基层医药》
CAS
2017年第5期743-746,共4页
Chinese Journal of Primary Medicine and Pharmacy
